Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

61.11 +1.37 (+2.29%)

Streaming Delayed Price Updated: 11:26 AM EDT, Aug 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet. ↗

January 07, 2025

One analyst says the six-month study was too short and the benefits could appear over time.

Via Investor's Business Daily

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic ↗

January 03, 2025

William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.

Via Benzinga

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood ↗

December 20, 2024

Ionis' Tryngolza receives FDA approval for familial chylomicronemia syndrome, showing significant triglyceride reduction and fewer pancreatitis events.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 12, 2024

Via Benzinga

Where Ionis Pharmaceuticals Stands With Analysts ↗

November 07, 2024

Via Benzinga

Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (13 Ratings) ↗

September 26, 2024

Via Benzinga

What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals ↗

August 26, 2024

Via Benzinga

12 Analysts Have This To Say About Ionis Pharmaceuticals ↗

August 02, 2024

Via Benzinga

Earnings Scheduled For February 19, 2025 ↗

February 19, 2025

Via Benzinga

Ionis to hold fourth quarter and full year 2024 financial results webcast

February 05, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

January 23, 2025

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA

From Biogen Inc.

Via GlobeNewswire

The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 5 Experts ↗

January 15, 2025

Via Benzinga

Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected ↗

January 07, 2025

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025.

Via Benzinga

The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 Experts ↗

December 20, 2024

Via Benzinga

A Glimpse Into The Expert Outlook On Ionis Pharmaceuticals Through 5 Analysts ↗

November 07, 2024

Via Benzinga

Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500 ↗

October 31, 2024

The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.

Via Benzinga

Topics ETFs Stocks

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗

October 18, 2024

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.

Via Investor's Business Daily

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

October 08, 2024

From Biogen Inc.

Via GlobeNewswire

The Latest Analyst Ratings For Ionis Pharmaceuticals ↗

July 16, 2024

Via Benzinga

Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts ↗

June 27, 2024

Via Benzinga

Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

September 10, 2024

Via Benzinga

Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗

September 10, 2024

Via Benzinga

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

September 04, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) ↗

June 03, 2024

Via Benzinga

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

September 04, 2024

From Biogen Inc.

Via GlobeNewswire

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst ↗

July 22, 2024

Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety...

Via Benzinga

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong ↗

July 22, 2024

Biogen previously decided against opting into Ionis' Angelman program.

Via Investor's Business Daily

RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 24, 2024

Via Benzinga

Masters In Trading - Saturday, June 22 ↗

June 22, 2024

In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio.

Via Talk Markets

Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile ↗

May 31, 2024

Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application submission expected this year.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.